FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3136229736> ?p ?o ?g. }

• W3136229736 abstract "Abstract Introduction To reduce malaria transmission in very low-endemic settings, screening and treatment near index cases (reactive case detection (RACD)), is widely practiced, but the rapid diagnostic tests (RDTs) used miss low-density infections. Presumptive treatment near index cases (reactive focal mass drug administration (rfMDA)) may be safe and more effective. Methods We conducted a cluster-randomised controlled trial in Eswatini, a very low-endemic setting. 77 clusters were randomised to rfMDA using dihydroartemisin-piperaquine (DP) or RACD involving RDTs and artemether lumefantrine (AL). Interventions were delivered by the local programme. An intention-to-treat analysis was used to compare cluster-level cumulative confirmed malaria incidence among clusters with cases. Secondary outcomes included safety and adherence. Results From Sept 2015–Aug 2017, 220 index cases from 47 clusters triggered 49 RACD events and 68 rfMDA events. RACD and rfMDA were delivered to 1696 and 1932 individuals, respectively. Index case and target population intervention coverages for both arms were 75.6%–81.4% and adherence to DP was 98.7%. For rfMDA versus RACD, cumulative incidences (per 1000 person-years) of all malaria were 2.11 (95% CI 1.73–2.59) and 1.97 (1.57–2.47), respectively; and of locally acquired malaria, they were 1.29 (95% CI 1.00–1.67) and 0.97 (0.71–1.34), respectively. Adjusting for imbalance in baseline incidence, incidence rate ratio (aIRR) for rfMDA versus RACD was 0.93 (95% CI 0.54–1.60) for all malaria and 0.77 (95% CI 0.38–1.56) for locally acquired malaria. No serious adverse events occurred. Conclusion In a very low-endemic, real-world setting, this trial is the first to evaluate rfMDA using DP. rfMDA was safe and resulted in lower cumulative incidence compared to RACD, but we were unable to confirm its effectiveness, potentially due to insufficient power. To assess impact of interventions in very low-endemic settings, multi-site, adaptive trials and use of complementary interventions may be needed. What is already known? Reactive case detection (RACD), or malaria testing and treatment in the vicinity of passively detected malaria cases, is a standard of care intervention used in low and very low transmission settings aiming for malaria elimination. Despite the use of RACD, progress toward malaria elimination has stalled in many countries and new strategies are needed. Reactive focal mass drug administration (rfMDA) is a transmission reducing strategy that has been shown to be effective in a low transmission setting, but there are no trial data from a very low transmission setting. What are the new findings? In a pragmatic, cluster-randomised controlled trial of rfMDA using dihydroartemisinin-piperaquine compared to RACD, we found that rfMDA was safe. rfMDA resulted in lower cumulative incidence, but we were unable to confirm its effectiveness compared to RACD, potentially due to insufficient power (we expected 63 total clusters would have incident cases, but observed 47). What do the new findings imply? When implemented in a real-world, very low transmission setting, rMDA was safe but evidence regarding its effectiveness to reduce transmission was weak. The challenge to show a statistically significant impact of a targeted community-based intervention in a very low transmission setting highlights the need for such trials to be multi-site, adaptive, and consider use of complementary interventions." @default.
• W3136229736 created "2021-03-29" @default.
• W3136229736 creator A5002863198 @default.
• W3136229736 creator A5006168829 @default.
• W3136229736 creator A5008906741 @default.
• W3136229736 creator A5010580970 @default.
• W3136229736 creator A5022271104 @default.
• W3136229736 creator A5023189613 @default.
• W3136229736 creator A5024890794 @default.
• W3136229736 creator A5025907369 @default.
• W3136229736 creator A5043212187 @default.
• W3136229736 creator A5046328079 @default.
• W3136229736 creator A5046916649 @default.
• W3136229736 creator A5049256910 @default.
• W3136229736 creator A5049912579 @default.
• W3136229736 creator A5053931704 @default.
• W3136229736 creator A5054207126 @default.
• W3136229736 creator A5054858957 @default.
• W3136229736 creator A5057765227 @default.
• W3136229736 creator A5059864994 @default.
• W3136229736 creator A5060638754 @default.
• W3136229736 creator A5078448184 @default.
• W3136229736 creator A5089290029 @default.
• W3136229736 creator A5090648373 @default.
• W3136229736 date "2021-03-12" @default.
• W3136229736 modified "2023-09-27" @default.
• W3136229736 title "Effectiveness and safety of reactive focal mass drug administration (rfMDA) using dihydroartemisinin-piperaquine to reduce malaria transmission in very low-endemic setting of Eswatini: a pragmatic cluster randomised controlled trial" @default.
• W3136229736 cites W1549510969 @default.
• W3136229736 cites W155390068 @default.
• W3136229736 cites W1966714873 @default.
• W3136229736 cites W2023978991 @default.
• W3136229736 cites W2035655846 @default.
• W3136229736 cites W2113932936 @default.
• W3136229736 cites W2114625697 @default.
• W3136229736 cites W2116530876 @default.
• W3136229736 cites W2127848106 @default.
• W3136229736 cites W2138055306 @default.
• W3136229736 cites W2550098977 @default.
• W3136229736 cites W2552385636 @default.
• W3136229736 cites W2555838895 @default.
• W3136229736 cites W2560080836 @default.
• W3136229736 cites W2735011376 @default.
• W3136229736 cites W2766353346 @default.
• W3136229736 cites W2796012534 @default.
• W3136229736 cites W2911417422 @default.
• W3136229736 cites W2945143255 @default.
• W3136229736 cites W2956358112 @default.
• W3136229736 cites W2971932246 @default.
• W3136229736 cites W3019315235 @default.
• W3136229736 cites W4210297421 @default.
• W3136229736 doi "https://doi.org/10.1101/2021.03.12.21252721" @default.
• W3136229736 hasPublicationYear "2021" @default.
• W3136229736 type Work @default.
• W3136229736 sameAs 3136229736 @default.
• W3136229736 citedByCount "1" @default.
• W3136229736 countsByYear W31362297362021 @default.
• W3136229736 crossrefType "posted-content" @default.
• W3136229736 hasAuthorship W3136229736A5002863198 @default.
• W3136229736 hasAuthorship W3136229736A5006168829 @default.
• W3136229736 hasAuthorship W3136229736A5008906741 @default.
• W3136229736 hasAuthorship W3136229736A5010580970 @default.
• W3136229736 hasAuthorship W3136229736A5022271104 @default.
• W3136229736 hasAuthorship W3136229736A5023189613 @default.
• W3136229736 hasAuthorship W3136229736A5024890794 @default.
• W3136229736 hasAuthorship W3136229736A5025907369 @default.
• W3136229736 hasAuthorship W3136229736A5043212187 @default.
• W3136229736 hasAuthorship W3136229736A5046328079 @default.
• W3136229736 hasAuthorship W3136229736A5046916649 @default.
• W3136229736 hasAuthorship W3136229736A5049256910 @default.
• W3136229736 hasAuthorship W3136229736A5049912579 @default.
• W3136229736 hasAuthorship W3136229736A5053931704 @default.
• W3136229736 hasAuthorship W3136229736A5054207126 @default.
• W3136229736 hasAuthorship W3136229736A5054858957 @default.
• W3136229736 hasAuthorship W3136229736A5057765227 @default.
• W3136229736 hasAuthorship W3136229736A5059864994 @default.
• W3136229736 hasAuthorship W3136229736A5060638754 @default.
• W3136229736 hasAuthorship W3136229736A5078448184 @default.
• W3136229736 hasAuthorship W3136229736A5089290029 @default.
• W3136229736 hasAuthorship W3136229736A5090648373 @default.
• W3136229736 hasBestOaLocation W31362297361 @default.
• W3136229736 hasConcept C120665830 @default.
• W3136229736 hasConcept C121332964 @default.
• W3136229736 hasConcept C126322002 @default.
• W3136229736 hasConcept C164866538 @default.
• W3136229736 hasConcept C199360897 @default.
• W3136229736 hasConcept C203014093 @default.
• W3136229736 hasConcept C2776120307 @default.
• W3136229736 hasConcept C2778048844 @default.
• W3136229736 hasConcept C2778371730 @default.
• W3136229736 hasConcept C2778629330 @default.
• W3136229736 hasConcept C2780133432 @default.
• W3136229736 hasConcept C2908647359 @default.
• W3136229736 hasConcept C41008148 @default.
• W3136229736 hasConcept C61511704 @default.
• W3136229736 hasConcept C71924100 @default.
• W3136229736 hasConcept C72563966 @default.
• W3136229736 hasConcept C88879693 @default.
• W3136229736 hasConcept C99454951 @default.
• W3136229736 hasConceptScore W3136229736C120665830 @default.
• W3136229736 hasConceptScore W3136229736C121332964 @default.

• next